Low-dose high-dose-rate brachytherapy in the treatment of facial lesions of cutaneous T-cell lymphoma

Jennifer A DeSimone; Emmanuella Guenova; Joi B Carter; Keri S Chaney; Julie R Aldridge; Claire M Noell; Andrew A Dorosario; Jorgen L Hansen; Thomas S Kupper; Phillip M Devlin

doi:10.1016/j.jaad.2012.12.975

Low-dose high-dose-rate brachytherapy in the treatment of facial lesions of cutaneous T-cell lymphoma

Jennifer A DeSimone
, Emmanuella Guenova
, Joi B Carter
, Keri S Chaney
, Julie R Aldridge
, Claire M Noell
, Andrew A Dorosario
, Jorgen L Hansen
, Thomas S Kupper
, Phillip M Devlin

Research output: Contribution to journal › Article › peer-review

Abstract

BACKGROUND: The use of many of the standard skin-directed mycosis fungoides (MF) therapies on facial skin may be limited by site-specific increased risks of side effects, excessive inflammation, and ocular toxicity.

OBJECTIVE: Our study aimed to describe the levels of erythema, scale, and induration of facial lesions in MF before and after low-dose high-dose-rate surface applicator brachytherapy and to examine the overall clinical response to brachytherapy.

METHODS: A total of 23 facial MF lesions in 10 patients were treated with high-dose-rate brachytherapy doses of 4 Gy per session for a total of 2 fractions at our multidisciplinary cutaneous oncology clinic between August 17, 2009, and March 12, 2012.

RESULTS: In all 23 lesions, dramatic clinical improvement was observed. Patients were followed up for a median of 6.3 months. No recurrences were reported in the follow-up period.

LIMITATIONS: Long-term follow-up is lacking. Reassessment of all included patients at annual intervals for a period of at least 5 years is the authors' goal.

CONCLUSION: Low-dose high-dose-rate brachytherapy using custom-made surface molds is a highly efficacious therapy in the treatment of facial lesions in MF.

Original language	English
Pages (from-to)	61-5
Number of pages	5
Journal	Journal of the American Academy of Dermatology
Volume	69
Issue number	1
DOIs	https://doi.org/10.1016/j.jaad.2012.12.975
Publication status	Published - Jul 2013
Externally published	Yes

Fields of science

302 Clinical Medicine

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/j.jaad.2012.12.975

Cite this

@article{fa3fe144990f45c2be72a95b662e1173,

title = "Low-dose high-dose-rate brachytherapy in the treatment of facial lesions of cutaneous T-cell lymphoma",

abstract = "BACKGROUND: The use of many of the standard skin-directed mycosis fungoides (MF) therapies on facial skin may be limited by site-specific increased risks of side effects, excessive inflammation, and ocular toxicity.OBJECTIVE: Our study aimed to describe the levels of erythema, scale, and induration of facial lesions in MF before and after low-dose high-dose-rate surface applicator brachytherapy and to examine the overall clinical response to brachytherapy.METHODS: A total of 23 facial MF lesions in 10 patients were treated with high-dose-rate brachytherapy doses of 4 Gy per session for a total of 2 fractions at our multidisciplinary cutaneous oncology clinic between August 17, 2009, and March 12, 2012.RESULTS: In all 23 lesions, dramatic clinical improvement was observed. Patients were followed up for a median of 6.3 months. No recurrences were reported in the follow-up period.LIMITATIONS: Long-term follow-up is lacking. Reassessment of all included patients at annual intervals for a period of at least 5 years is the authors' goal.CONCLUSION: Low-dose high-dose-rate brachytherapy using custom-made surface molds is a highly efficacious therapy in the treatment of facial lesions in MF.",

keywords = "Aged, Aged, 80 and over, Brachytherapy/methods, Dose-Response Relationship, Radiation, Erythema/etiology, Facial Neoplasms/radiotherapy, Female, Humans, Male, Middle Aged, Mycosis Fungoides/radiotherapy, Radiotherapy/adverse effects, Radiotherapy Dosage, Skin Neoplasms/radiotherapy, Treatment Outcome",

author = "DeSimone, \{Jennifer A\} and Emmanuella Guenova and Carter, \{Joi B\} and Chaney, \{Keri S\} and Aldridge, \{Julie R\} and Noell, \{Claire M\} and Dorosario, \{Andrew A\} and Hansen, \{Jorgen L\} and Kupper, \{Thomas S\} and Devlin, \{Phillip M\}",

year = "2013",

month = jul,

doi = "10.1016/j.jaad.2012.12.975",

language = "English",

volume = "69",

pages = "61--5",

journal = "Journal of the American Academy of Dermatology",

issn = "1097-6787",

number = "1",

}

TY - JOUR

T1 - Low-dose high-dose-rate brachytherapy in the treatment of facial lesions of cutaneous T-cell lymphoma

AU - DeSimone, Jennifer A

AU - Guenova, Emmanuella

AU - Carter, Joi B

AU - Chaney, Keri S

AU - Aldridge, Julie R

AU - Noell, Claire M

AU - Dorosario, Andrew A

AU - Hansen, Jorgen L

AU - Kupper, Thomas S

AU - Devlin, Phillip M

PY - 2013/7

Y1 - 2013/7

N2 - BACKGROUND: The use of many of the standard skin-directed mycosis fungoides (MF) therapies on facial skin may be limited by site-specific increased risks of side effects, excessive inflammation, and ocular toxicity.OBJECTIVE: Our study aimed to describe the levels of erythema, scale, and induration of facial lesions in MF before and after low-dose high-dose-rate surface applicator brachytherapy and to examine the overall clinical response to brachytherapy.METHODS: A total of 23 facial MF lesions in 10 patients were treated with high-dose-rate brachytherapy doses of 4 Gy per session for a total of 2 fractions at our multidisciplinary cutaneous oncology clinic between August 17, 2009, and March 12, 2012.RESULTS: In all 23 lesions, dramatic clinical improvement was observed. Patients were followed up for a median of 6.3 months. No recurrences were reported in the follow-up period.LIMITATIONS: Long-term follow-up is lacking. Reassessment of all included patients at annual intervals for a period of at least 5 years is the authors' goal.CONCLUSION: Low-dose high-dose-rate brachytherapy using custom-made surface molds is a highly efficacious therapy in the treatment of facial lesions in MF.

AB - BACKGROUND: The use of many of the standard skin-directed mycosis fungoides (MF) therapies on facial skin may be limited by site-specific increased risks of side effects, excessive inflammation, and ocular toxicity.OBJECTIVE: Our study aimed to describe the levels of erythema, scale, and induration of facial lesions in MF before and after low-dose high-dose-rate surface applicator brachytherapy and to examine the overall clinical response to brachytherapy.METHODS: A total of 23 facial MF lesions in 10 patients were treated with high-dose-rate brachytherapy doses of 4 Gy per session for a total of 2 fractions at our multidisciplinary cutaneous oncology clinic between August 17, 2009, and March 12, 2012.RESULTS: In all 23 lesions, dramatic clinical improvement was observed. Patients were followed up for a median of 6.3 months. No recurrences were reported in the follow-up period.LIMITATIONS: Long-term follow-up is lacking. Reassessment of all included patients at annual intervals for a period of at least 5 years is the authors' goal.CONCLUSION: Low-dose high-dose-rate brachytherapy using custom-made surface molds is a highly efficacious therapy in the treatment of facial lesions in MF.

KW - Aged

KW - Aged, 80 and over

KW - Brachytherapy/methods

KW - Dose-Response Relationship, Radiation

KW - Erythema/etiology

KW - Facial Neoplasms/radiotherapy

KW - Female

KW - Humans

KW - Male

KW - Middle Aged

KW - Mycosis Fungoides/radiotherapy

KW - Radiotherapy/adverse effects

KW - Radiotherapy Dosage

KW - Skin Neoplasms/radiotherapy

KW - Treatment Outcome

UR - https://www.scopus.com/pages/publications/84879089345

U2 - 10.1016/j.jaad.2012.12.975

DO - 10.1016/j.jaad.2012.12.975

M3 - Article

C2 - 23453243

SN - 1097-6787

VL - 69

SP - 61

EP - 65

JO - Journal of the American Academy of Dermatology

JF - Journal of the American Academy of Dermatology

IS - 1

ER -

Low-dose high-dose-rate brachytherapy in the treatment of facial lesions of cutaneous T-cell lymphoma

Abstract

Fields of science

UN SDGs

Access to Document

Other files and links

Cite this